浙江寿仙谷医药股份有限公司 2025 年第二次投资者接待日活动召开情况 为进一步提高企业治理水平，增进公司与广大投资者之间的信息沟通，公司 2025 年第二次投资者接待日活动于 2025 年 12 月 23 日举行，公司组织投资者们 参观了寿仙谷有机国药基地、洋垄厂区（未来工厂+生物育种创新中心）及寿仙 谷文化馆，管理层就公司经营情况、科研进展等与广大投资者进行了充分交流， 同时解答了投资者较为关注的问题。具体情况如下： 一、活动基本情况 1、活动时间：2025 年 12 月 23 日 2、活动地点： （1）上午：公司基地—寿仙谷有机国药养生园；洋垄厂区—未来工厂+生物 育种创新中心 二、活动主要交流情况 1、核心产品省外营销拓展情况，以及公司对行业的发展情况的判断 答：公司在省外的业务拓展主要围绕去壁灵芝孢子粉核心产品的推广与销售。今年通过 省外渠道经销商和品牌加盟商两种模式进行渠道拓展。 从当前的宏观形势看，医药内需板块在未来一两年内整体情况将继续保持一定的复苏压 力。随着国家进入高质量发展，人民群众日益追求高水平健康的趋势不会变，中国进入银发 经济时代，中医药的功效被越来越多的人接受和认可的现实不会变， ...

| | | 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、 议案审议情况 审议结果：通过 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | | 票数 | 比例（%） | 票数 | 比例 （%） | 票数 | 比例 （%） | | A 股 | 3,798,315 | 92.8616 | 226,721 | 5.5429 | 65,260 | 1.5955 | 2、 议案名称：关于公司申请 2026 年度综合授信额度及相关担保事项的议案 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 218 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 75,843,185 | | 3、出席会议的股东所持有表决权股 ...

下 天册律师事务所 T T & C L A W F L R M 法律意见书 浙江天册律师事务所 关于 浙江寿仙谷医药股份有限公司 2025 年第二次临时股东会的 法律意见书 天册律师事务所 T & C LAW FIRM 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话: 0571-87901111 传真: 0571-87901500 2025 2025 1 12 23 2025 12 23 9:15-9:25 9:30-11:30 13:00-15:00 2025 12 23 9:15-15:00 2025 2025 11 29 1. 2026 2. 2026 3. 2026 4. < > 1 2 3 4 2 16 73,471,077 37.0610 % 202 2,372,108 1.1966% 1. 2026 3,798,315 226,721 65,260 92.8616% 2. 2026 75,518,704 271,021 53,460 99.5721% 3. 2026 75,435,464 349,981 57,740 99.4624% 3 4. < > 75,502 ...

证券日报网讯12月15日，寿仙谷（603896）在互动平台回答投资者提问时表示，目前，公司已进驻阿里 国际站和亚马逊平台，尚未实现产品直接出口欧盟国家。公司如有国际业务重大进展，将严格按规定及 时履行信息披露义务，敬请关注公司公告。 ...

证券日报网讯 12月15日，寿仙谷（603896）在互动平台回答投资者提问时表示，目前，公司互联网销 售平台主要为天猫、京东，还包括寿仙谷官网、寿仙谷官方商城（微信）、抖音、快手等。各主要平台 销售额的占比公司暂未对外披露。 ...

格隆汇12月15日丨寿仙谷(603896.SH)在投资者互动平台表示，目前，公司已进驻阿里国际站和亚马逊 平台，尚未实现产品直接出口欧盟国家。 ...

格隆汇12月15日丨寿仙谷(603896.SH)在投资者互动平台表示，目前，公司已进驻阿里国际站和亚马逊 平台，尚未实现产品直接出口欧盟国家。 ...

声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 有投资者在互动平台向寿仙谷提问："请问近两年是否出口欧盟国家？" 针对上述提问，寿仙谷回应称："您好！感谢您的关注！目前，公司已进驻阿里国际站和亚马逊平台， 尚未实现产品直接出口欧盟国家。公司如有国际业务重大进展，将严格按规定及时履行信息披露义务， 敬请关注公司公告。谢谢！" 作者：公告君 ...

Investment Rating - The industry rating is maintained at "Overweight" [6] Core Insights - The Chinese medicine sector experienced a significant decline, with the Chinese medicine index dropping by 2.03% last week, while other pharmaceutical sub-sectors also faced declines, except for medical services which saw a 1.67% increase [1][19] - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.17X, down by 0.55X week-on-week, while the price-to-book (PB) ratio is 2.29X, down by 0.04X week-on-week [2] - The demand for flu-related and tonic herbs has increased, leading to a rise in the price index of Chinese medicinal materials, which is expected to continue to rise slightly in the future [3] - The national medical insurance work conference highlighted the restructuring of prices and market patterns as a major direction for the Chinese medicine industry in 2026, emphasizing the importance of collective procurement and support for innovation in the industry [4][9] Summary by Sections Market Performance - The Chinese medicine index closed at 6372.09 points, down 2.03% last week, with only the medical services sector recording positive returns [1][19] Valuation - The current PE ratio for the Chinese medicine sector is 27.17X, with a year-high of 30.26X and a year-low of 24.72X, placing it at the 28.41% percentile since 2013 [2] Supply Chain Insights - The price index for Chinese medicinal materials rose to 225.57 points, a 0.4% increase from the previous week, driven by increased demand due to the flu outbreak and winter tonic herbs [3] Policy and Market Trends - The 2026 direction for the Chinese medicine industry includes continued promotion of collective procurement and support for innovation, with an emphasis on price governance and market restructuring [4][10] - The focus on long-term care insurance is expected to increase demand for Chinese medicine products, particularly in the context of an aging population [9] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, with specific recommendations for companies with strong R&D capabilities and unique products [10][11]

Core Insights - The Chinese health industry is entering a significant growth phase, driven by an aging population and increasing acceptance of traditional Chinese medicine [2] - Shouxiangu aims to become a leading brand in organic Chinese medicine and global Lingzhi products, focusing on product quality and consumer trust [3] Company Strategy - Shouxiangu's main products include third-generation wall-breaking Lingzhi spore powder and Dendrobium candidum series, with Lingzhi spore powder accounting for approximately 72% of sales in the first half of 2025 [3] - The company is expanding its market presence outside Zhejiang province, where current sales account for less than 10% [3][4] - Shouxiangu plans to adopt a dual approach for expansion, including learning from successful distributors and forming strategic partnerships with well-known pharmaceutical distribution companies [4] Digital Transformation - The company is leveraging AI technology to enhance production efficiency and product quality, while also utilizing digital marketing to improve customer engagement and conversion rates [4] Industry Challenges - The traditional Chinese medicine sector faces cyclical pressures from high-end consumption contraction and inventory issues, alongside long-term structural challenges [4] - The industry is experiencing a shift in consumer demographics, with younger consumers becoming a significant market segment [4] Marketing and Product Innovation - Shouxiangu is enhancing brand visibility through sponsorships and engaging with new media platforms for broader consumer reach [5] - The company is diversifying its product offerings to appeal to younger consumers, including ready-to-drink products and innovative formats like capsules and oral liquids [5]